Take away the red and white blood cells from blood and you get plasma, a protein-rich fluid. CSL Behring is among the world's largest fully integrated plasma collection companies. Through subsidiary CSL Plasma (formerly ZLB Plasma), the company collects plasma through dozens of facilities in the US and Germany. CSL Behring then develops plasma-based protein biotherapeutics to treat a range of health ailments, including bleeding disorders (such as hemophilia), immune system deficiencies, and respiratory disease (including emphysema). Biotherapeutics are also used in critical care settings for surgical and wound healing applications. CSL Behring is a subsidiary of Australian biopharmaceutical firm CSL Limited.
The company boasts a global presence through its more than two dozen regional sales offices. Outside the US, CSL Behring sells products in Argentina, Austria, Belgium/Luxemburg, Brazil, Canada, China, Denmark, France, Germany, Greece, Hong Kong, Italy, Japan, Mexico, the Netherlands, Sweden, Portugal, Spain, Switzerland, and the UK. The company maintains research and development facilities in Illinois and Pennsylvania, as well as overseas in Germany and Switzerland. Manufacturing takes place in Germany, Switzerland, and in the US in Illinois.
CSL Behring has biotherapeutic manufacturing operations in the US, Germany, and Switzerland, and it has satellite sales offices in another 20 countries worldwide. Plasma collection subsidiary CSL Plasma, which changed its name from ZLB Plasma in 2009 to align its operations with the parent organization, operates about 60 plasma collection centers in the US and 10 in Germany. CSL Plasma is one of the world's largest plasma collection networks.
To expand its product line to treat a wider variety of diseases, CSL Behring regularly conducts research and development activities both internally and through partnerships. The process is time-consuming and tedious. The FDA in 2009 approved two new products: Riastap for acute bleeding episodes in patients with genetic protein deficiencies and Berinert for attacks of hereditary angioderma (rapid skin swelling).
Net revenue increased some 5% in 2011 as compared to 2010 due to rising demand for its products across all regions. CSL Behring saw sales rise, thanks to growth for its Hizentra-brand subcutaneous immunoglobulin in North America, as well as its Privigen brand of intravenous immunoglobulin.
CSL Behring takes the second part of its name from Emil von Behring, a German doctor who worked to find treatments for infectious diseases. Formerly known as ZLB Behring, the company was formed in 2004 when parent CSL Limited acquired Aventis Behring and merged it with its ZLB Bioplasma unit.